Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
Conditions
Keywords
Treatment naive, Interferon free, HCV, Chronic Hepatitis C, Hepatitis C Genotype 1a, Hepatitis C, pegylated-interferon (pegIFN)/ribavirin (RBV) experienced
Brief summary
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults receiving treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir coadministered with ribavirin (RBV) for 12 weeks.
Detailed description
A study to evaluate the role of ombitasvir/paritaprevir/ritonavir and dasabuvir coadministered with RBV treatment leading to sustained virologic response 12 weeks post-dosing (SVR12) on the changes from baseline in IFN-stimulated gene (ISG) expression in peripheral blood mononucleated cells (PBMCs) in HCV GT 1a-infected adult participants.
Interventions
Sponsors
AbbVie
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Screening laboratory result indicating hepatitis C viral (HCV) genotype (GT) 1a infection. 2. Chronic HCV infection. 3. Participants must be non-cirrhotic. 4. Participants must be treatment-naïve or have documentation that they were adherent to prior pegIFN/RBV combination therapy and meet the criteria of prior pegylated-interferon (pegIFN)/ribavirin (RBV) treatment failure. 5. Participants must meet specific human leukocyte antigen (HLA) allele requirements.
Exclusion criteria
1. Women who are pregnant or breastfeeding. 2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab) positive immunoassay. 3. Clinically significant abnormalities or co-morbidities, other than HCV infection, that make the subject unsuitable for this study or treatment. 4. Current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-HCV agents other than pegIFN or RBV (including previous exposure to paritaprevir, ombitasvir, or dasabuvir), or receipt of any investigational product within 6 weeks prior to study drug administration. 5. History of solid organ transplant. 6. Screening laboratory analysis that shows abnormal results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | Week 0 to Post-Treatment Week 12 | The changes from week 0 to post-treatment (PT) week 12 in key ISG expression in PBMCs for participants achieving sustained virologic response 12 weeks PT (SVR12) where SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\<LLOQ) 12 weeks after the last dose of study drug. For each key ISG, fold change was defined as the ratio of the difference between PT Week 12 and baseline expressions over the baseline expression. |
Participant flow
Pre-assignment details
The intent-to-treat (ITT) population consisted of all enrolled participants who received at least one dose of study drug.
Participants by arm
| Arm | Count |
|---|---|
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg QD) + dasabuvir (250 mg BID) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID) | 25 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Lost to Follow-up | 1 |
Baseline characteristics
| Characteristic | Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV |
|---|---|
| Age, Continuous | 44.8 years STANDARD_DEVIATION 12.61 |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 24 / 25 |
| serious Total, serious adverse events | 2 / 25 |
Outcome results
Primary
Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12
The changes from week 0 to post-treatment (PT) week 12 in key ISG expression in PBMCs for participants achieving sustained virologic response 12 weeks PT (SVR12) where SVR12 was defined as hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (\<LLOQ) 12 weeks after the last dose of study drug. For each key ISG, fold change was defined as the ratio of the difference between PT Week 12 and baseline expressions over the baseline expression.
Time frame: Week 0 to Post-Treatment Week 12
Population: All participants who achieved SVR12 and had both baseline and post-baseline value at Post-Treatment Week 12 were included in this analyses..
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MX2 | -0.101 Fold change | Standard Deviation 0.6188 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CXCL10 | -0.464 Fold change | Standard Deviation 0.6143 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | ISG15 | -0.148 Fold change | Standard Deviation 0.7458 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CXCL11 | -0.611 Fold change | Standard Deviation 0.309 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MX1 | -0.399 Fold change | Standard Deviation 0.3013 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFI27 | -0.462 Fold change | Standard Deviation 0.4624 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | OAS2 | -0.168 Fold change | Standard Deviation 0.5168 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | DDX60 | -0.016 Fold change | Standard Deviation 0.5696 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFIT3 | -0.543 Fold change | Standard Deviation 0.335 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFI44 | -0.467 Fold change | Standard Deviation 0.2569 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | STAT1 | -0.301 Fold change | Standard Deviation 0.343 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CXCL9 | -0.552 Fold change | Standard Deviation 0.2816 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFIT1 | -0.440 Fold change | Standard Deviation 0.4441 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | HERC5 | -0.358 Fold change | Standard Deviation 0.2827 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IRF7 | -0.171 Fold change | Standard Deviation 0.4273 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | OAS1 | 0.284 Fold change | Standard Deviation 1.4668 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | PLSCR1 | -0.255 Fold change | Standard Deviation 0.3688 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IRF9 | -0.205 Fold change | Standard Deviation 0.2809 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFIH1 | -0.321 Fold change | Standard Deviation 0.3213 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | TRIM14 | 0.022 Fold change | Standard Deviation 0.5282 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IRF1 | -0.130 Fold change | Standard Deviation 0.6497 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IRF3 | 0.044 Fold change | Standard Deviation 0.6307 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | STAT2 | -0.051 Fold change | Standard Deviation 0.5762 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNG | 0.516 Fold change | Standard Deviation 1.4653 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNL1 | -0.361 Fold change | Standard Deviation 0.3753 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNL2 | -0.199 Fold change | Standard Deviation 0.7031 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNL3 | -0.205 Fold change | Standard Deviation 0.4306 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNL4 | -0.228 Fold change | Standard Deviation 0.7298 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNGR1 | -0.046 Fold change | Standard Deviation 0.3008 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | ADAR | -0.212 Fold change | Standard Deviation 0.2314 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | ALG10 | -0.083 Fold change | Standard Deviation 0.7491 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | BCHE | -0.101 Fold change | Standard Deviation 0.5739 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CCL2 | 0.200 Fold change | Standard Deviation 1.5071 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CCL4 | 0.638 Fold change | Standard Deviation 1.7396 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CD163 | 0.556 Fold change | Standard Deviation 2.7478 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CXCL5 | 1.085 Fold change | Standard Deviation 2.7539 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | CXCR3 | 0.308 Fold change | Standard Deviation 0.5236 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | DDIT4 | 0.029 Fold change | Standard Deviation 1.2134 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | DDX58 | 0.388 Fold change | Standard Deviation 1.2231 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | DPP4 | 0.869 Fold change | Standard Deviation 1.573 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | EIF2AK2 | -0.317 Fold change | Standard Deviation 0.2521 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | GBP1 | -0.288 Fold change | Standard Deviation 0.4421 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | GCKR | 0.009 Fold change | Standard Deviation 0.5267 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | GUCY1B3 | 0.350 Fold change | Standard Deviation 0.7909 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | HELZ2 | -0.232 Fold change | Standard Deviation 0.5124 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | HERC6 | -0.074 Fold change | Standard Deviation 0.3294 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFI35 | -0.023 Fold change | Standard Deviation 0.6428 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFI44L | -0.554 Fold change | Standard Deviation 0.4068 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFI6 | -0.464 Fold change | Standard Deviation 0.301 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFIT2 | -0.365 Fold change | Standard Deviation 0.4118 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFIT5 | -0.291 Fold change | Standard Deviation 0.2085 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFITM1 | -0.066 Fold change | Standard Deviation 0.3696 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFITM2 | 0.158 Fold change | Standard Deviation 0.7905 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFITM3 | -0.423 Fold change | Standard Deviation 0.3313 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNA | -0.202 Fold change | Standard Deviation 0.5037 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IFNB | -0.167 Fold change | Standard Deviation 0.4427 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IL10 | 0.202 Fold change | Standard Deviation 0.8216 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IL18 | -0.078 Fold change | Standard Deviation 0.2695 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | IRF2 | 0.311 Fold change | Standard Deviation 1.0487 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | ISG20 | 0.156 Fold change | Standard Deviation 1.0071 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MAP3K14 | -0.072 Fold change | Standard Deviation 0.2983 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MOV10 | -0.185 Fold change | Standard Deviation 0.4048 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MS4A4A | -0.005 Fold change | Standard Deviation 0.7458 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | MYST1 | -0.057 Fold change | Standard Deviation 0.2404 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | NOS2A | 0.249 Fold change | Standard Deviation 0.8288 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | NT5C3 | 0.017 Fold change | Standard Deviation 0.3577 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | OASL | -0.233 Fold change | Standard Deviation 0.6984 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | PPP3CB | 0.011 Fold change | Standard Deviation 0.1956 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | RNASEL | 0.395 Fold change | Standard Deviation 0.9973 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | RSAD2 | -0.406 Fold change | Standard Deviation 0.3202 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | SLC27A2 | 0.022 Fold change | Standard Deviation 0.9149 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | SOCS1 | 1.313 Fold change | Standard Deviation 3.5778 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | SOCS3 | 0.025 Fold change | Standard Deviation 1.1773 |
| Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + RBV | Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 | USP18 | -0.288 Fold change | Standard Deviation 0.3092 |